Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Revenue (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Revenue for 8 consecutive years, with $11.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue rose 338.49% year-over-year to $11.7 million, compared with a TTM value of $3.0 million through Sep 2025, down 50.85%, and an annual FY2024 reading of $800000.0, down 84.91% over the prior year.
  • Revenue was $11.7 million for Q3 2025 at Bicycle Therapeutics, up from $2.9 million in the prior quarter.
  • Across five years, Revenue topped out at $11.7 million in Q3 2025 and bottomed at -$21.6 million in Q4 2024.
  • Average Revenue over 5 years is $3.3 million, with a median of $4.3 million recorded in 2021.
  • The sharpest move saw Revenue surged 950.0% in 2022, then plummeted 294.58% in 2023.
  • Year by year, Revenue stood at $800000.0 in 2021, then soared by 950.0% to $8.4 million in 2022, then tumbled by 294.58% to -$16.3 million in 2023, then crashed by 32.38% to -$21.6 million in 2024, then surged by 154.23% to $11.7 million in 2025.
  • Business Quant data shows Revenue for BCYC at $11.7 million in Q3 2025, $2.9 million in Q2 2025, and $10.0 million in Q1 2025.